Pharmaron Beijing Co., Ltd.
Pharmaron Beijing Co., Ltd. (3759.HK) Stock Overview
Explore Pharmaron Beijing Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.
3759.HK Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Pharmaron Beijing Co., Ltd. (3759.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $6.05.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 13.71 and a market capitalization of 43.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Boliang Lou
21,370
6 Taihe Road, Beijing
2019